News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Aduro Biotech Announces Collaboration With Johns Hopkins University to Evaluate Aduro Therapeutic Melanoma Vaccines in Combination With Anti-PD-1


4/22/2013 12:54:39 PM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BERKELEY, Calif.--(BUSINESS WIRE)--Aduro BioTech, Inc. announces a collaboration with Charles G. Drake, M.D., Ph.D., Associate Professor of Oncology, Immunology and Urology at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center to evaluate the therapeutic approach of anti-PD-1 in combination with one or both of Aduro’s vaccine technologies based on live, attenuated Listeria monocytogenes and STING-activating adjuvants. The collaboration will be supported in part by a recent grant award from the Melanoma Research Foundation to Dr. Drake.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES